SCHEMBL26985264

SCHEMBL26985264

CN(C#N)c1cc(Br)ccc1[N+](=O)[O-]

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
S100A4 P26447 1/20 0.37
TRPV1 Q8NER1 1/20 0.37
CYP3A4 P08684 2/20 0.36
TSHR P16473 1/20 0.36
EGFR P00533 2/20 0.36
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 3/20 0.35
HTT P42858 1/20 0.35
HCAR3 P49019 1/20 0.35
VCAM1 P19320 4/20 0.34
CYP1A2 P05177 2/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
CYP2C9 P11712 1/20 0.33
HPGD P15428 1/20 0.33
RECQL P46063 1/20 0.33
BLM P54132 1/20 0.33
HSD17B10 Q99714 1/20 0.33
TDP1 Q9NUW8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30727350 1.00 MAPT (0.38) MAPTS100A4TRPV1CYP3A4TSHR
SCHEMBL1844442 0.82 MAPT (0.47) MAPTS100A4TRPV1CYP3A4TSHR
SCHEMBL30490321 0.78 MAPT (0.40) MAPTS100A4TRPV1CYP3A4TSHR
SCHEMBL20150149 0.75 CYP19A1 (0.49) MAPTS100A4TRPV1EGFRKDM4E
SCHEMBL29739895 0.75 CYP19A1 (0.49) MAPTS100A4TRPV1EGFRKDM4E
SCHEMBL7403916 0.74 MEN1 (0.53) MAPTS100A4TRPV1EGFRKDM4E
SCHEMBL15616427 0.73 ALDH1A1 (0.48) MAPTS100A4TRPV1CYP3A4TSHR
SCHEMBL18508230 0.72 ALDH1A1 (0.40) MAPTS100A4TRPV1KDM4EALDH1A1
SCHEMBL6541812 0.72 KMT2A (0.46) MAPTTSHRKDM4EALDH1A1HCAR3
SCHEMBL30018445 0.71 ALDH1A1 (0.58) MAPTS100A4TRPV1EGFRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-11-20 US disclosed
EP-4547671-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER Anima Biotech Inc. (US) 2025-05-07 EP disclosed
WO-2024010761-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2024-01-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250353862-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 MAPT 3215/4885S100A4 2010/4885TRPV1 4847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.